Sanofi

NASDAQ:SNY

Drug Manufacturers - General

Healthcare
$47.12 -0.73%

-$0.31 today

Market cap
$113.15B
Beta
0.28
P/E (TTM)
8.5
EPS (TTM)
$8.60
Dividend yield
5.62%
52W Low $41.86High $52.68

Volume 2.32M

Average 2.78M

SNY Income Before Tax

Profit after all operating and non-operating items but before income tax.

SanofiNASDAQ: SNY

Income Before Tax · Q2 FY2026 · quarter ended Jun 2026

Income before tax declines year over year

Q2 FY2026 income before tax of €828M fell 43.6% year over year, behind the -32.5% change in trailing-twelve-month income before tax. Sequentially, it fell 58.9% from the prior quarter. Over 3 fiscal years it compounded at -15.5% a year.

Context

  • Income before tax amounted to 12.9% of revenue in FY2025, down 2.4 pp from a year earlier.
  • Income before tax increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -43.6% toward the trailing-twelve-month pace of -32.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
€828M-58.9% QoQ
Last fiscal yearDec 2025
€6.02B-10.9% YoY
LTMJun 2026
€5.2B-32.5% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-43.6%——
1 year-10.9%——
3-year CAGR-15.5%——
5-year CAGR——
10-year CAGR——

Income Before Tax history

EUR · from the income statement

Latest · FY2025
6.02B EUR
Year-over-year change
-10.9%
4-year CAGR
-6.4%

Income Before Tax vs competitors

How SNY compares with its peers on the latest reported figures

  • Peers report in different currencies, so income before tax is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -32.5% is the 8th highest of 11, against a peer median of +10.7%.
  • Income before tax amounts to 10.6% of revenue for SNY, versus a peer median of 22.8%.
SNY Competitors
Income Before Tax for SNY and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NVONovo Nordisk A/SLTM Jun 2026DKK 148.75B DKK+5.7%+23.6%45.2%
LLYEli Lilly and CompanyLTM Jun 2026$33.6B USD+99.3%+55.8%42.2%
NVSNovartis AGLTM Jun 2026$15.52B USD-0.5%+31.8%27.9%
AZNAstraZeneca PLCLTM Sep 2026$13.25B USD+15.8%+70.5%21.3%
BMYBristol-Myers Squibb CompanyLTM Jun 2026$11.91B USD+80.6%+6.5%24.2%
AMGNAmgen Inc.LTM Jun 2026$10.29B USD+38.6%+6.9%27.0%
MRKMerck & Co., Inc.LTM Jun 2026$5.95B USD-69.0%+8.6%9.0%
GSKGSK plcLTM Jun 2026£5.9B GBP+27.7%+9.6%17.8%
SNYSanofiLTM Jun 2026€5.2B EUR-32.5%-15.5%10.6%
PFEPfizer Inc.LTM Jun 2026$4.21B USD-60.0%-40.0%6.6%
GILDGilead Sciences, Inc.LTM Jun 2026-$1.96B USD-127.1%+19.0%6.4%
Peer median (excluding SNY) —+10.7%+14.3%22.8%

Competitors are the stored peer set for SNY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue39.18B40.56B41.62B44.29B46.72B
Cost of Revenue12.26B11.88B12.63B13.21B13.05B
Gross Profit26.92B28.68B28.99B31.08B33.67B
Gross Margin68.7%70.7%69.7%70.2%72.1%
Research & Development5.69B6.5B6.51B7.39B7.84B
Selling, General & Admin9.56B8.74B8.93B9.18B10.24B
Operating Expenses18.79B18.52B22.03B23.83B24.07B
Depreciation & Amortization3.35B3.11B4.43B3.59B5.68B
EBITDA11.54B13.51B11.39B11.03B12.48B
EBITDA Margin29.5%33.3%27.4%24.9%26.7%
Operating Income8.13B10.16B6.96B7.25B9.6B
Operating Margin20.7%25.1%16.7%16.4%20.5%
Interest Income3.13M168.96M530.5M457.53M331M
Interest Expense377.37M384.8M512.82M622.58M626M
Other Income / Expenses(289M)(170M)(845M)(494M)(3.58B)
Income Before Tax7.84B9.99B6.12B6.76B6.02B
Pre-Tax Margin20.0%24.6%14.7%15.3%12.9%
Income Tax Expense1.56B1.91B1.02B1.2B1.04B
Net Income6.22B8.37B5.4B5.56B7.81B
Net Margin15.9%20.6%13.0%12.6%16.7%
EPS (Basic)2.493.192.152.193.20
EPS (Diluted)2.493.182.152.193.20
Weighted Avg Shares2.51B2.5B2.5B2.5B2.44B
Weighted Avg Shares (Diluted)2.51B2.5B2.51B2.5B2.44B

Sanofi

NASDAQ:SNY

Intrinsic Alpha fair value

Locked

Current Price

$47.12

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.